Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1991 Feb;54(2):119–123. doi: 10.1136/jnnp.54.2.119

Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy.

A P van Zanten 1, A Twijnstra 1, B W Ongerboer de Visser 1, P van Heerde 1, A A Hart 1, W J Nooyen 1
PMCID: PMC1014345  PMID: 2019836

Abstract

The results of cerebrospinal fluid (CSF) biochemical markers were compared with conventional CSF cytology in patients treated for leptomeningeal metastases from extra cranial malignancies. For lumbar CSF, before treatment, no statistically significant difference of the probabilities of being positive was found between CSF cytology and a classification by linear discriminant analysis, based on patient's age, of beta-glucuronidase and beta 2-microglobulin. During treatment, classification by linear discriminant analysis was found more often positive than cytology. Possible mechanisms for this difference are discussed. For ventricular CSF a correlation was found between CSF cytology and beta-glucuronidase for solid tumours, and between CSF cytology and beta 2-microglobulin for haematological malignancies. Reference values for ventricular protein, CEA beta-glucuronidase and beta 2-microglobulin were obtained for cytological negative samples.

Full text

PDF
119

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boogerd W., Vroom T. M., van Heerde P., Brutel de la Rivière G., Peterse J. L., van der Sande J. J. CSF cytology versus immunocytochemistry in meningeal carcinomatosis. J Neurol Neurosurg Psychiatry. 1988 Jan;51(1):142–145. doi: 10.1136/jnnp.51.1.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Coakham H. B., Garson J. A., Brownell B., Kemshead J. T. Diagnosis of cerebral neoplasms using monoclonal antibodies. Prog Exp Tumor Res. 1985;29:57–77. doi: 10.1159/000411626. [DOI] [PubMed] [Google Scholar]
  3. Duttera M. J., Bleyer W. A., Pomeroy T. C., Leventhal C. M., Leventhal B. G. Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia. Lancet. 1973 Sep 29;2(7831):703–707. doi: 10.1016/s0140-6736(73)92539-7. [DOI] [PubMed] [Google Scholar]
  4. Glass J. P., Melamed M., Chernik N. L., Posner J. B. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979 Oct;29(10):1369–1375. doi: 10.1212/wnl.29.10.1369. [DOI] [PubMed] [Google Scholar]
  5. Jacobi C., Reiber H., Felgenhauer K. The clinical relevance of locally produced carcinoembryonic antigen in cerebrospinal fluid. J Neurol. 1986 Nov;233(6):358–361. doi: 10.1007/BF00313922. [DOI] [PubMed] [Google Scholar]
  6. MEULEMANS O. Determination of total protein in spinal fluid with sulphosalicylic acid and trichloroacetic acid. Clin Chim Acta. 1960 Sep;5:757–761. doi: 10.1016/0009-8981(60)90020-6. [DOI] [PubMed] [Google Scholar]
  7. Murray J. J., Greco F. A., Wolff S. N., Hainsworth J. D. Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med. 1983 Aug;75(2):289–294. doi: 10.1016/0002-9343(83)91207-x. [DOI] [PubMed] [Google Scholar]
  8. Nagelkerke A. F., van Kamp G. J., Veerman A. J., de Waal F. C. Unreliability of beta-2-microglobulin in early detection of central nervous system relapse in acute lymphoblastic leukemia. Eur J Cancer Clin Oncol. 1985 Jun;21(6):659–663. doi: 10.1016/0277-5379(85)90261-5. [DOI] [PubMed] [Google Scholar]
  9. Neumann G. J. The determination of normal ranges from routine laboratory data. Clin Chem. 1968 Oct;14(10):979–988. [PubMed] [Google Scholar]
  10. Ongerboer de Visser B. W., Somers R., Nooyen W. H., van Heerde P., Hart A. A., McVie J. G. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology. 1983 Dec;33(12):1565–1572. doi: 10.1212/wnl.33.12.1565. [DOI] [PubMed] [Google Scholar]
  11. Persijn J. P., Korsten C. B. The development of a radioimmuno-assay for carcino-embryonic antigen with some applications. Clinical evaluation of carcino-embryonic antigen, I. J Clin Chem Clin Biochem. 1976 Aug;14(8):377–387. doi: 10.1515/cclm.1976.14.1-12.377. [DOI] [PubMed] [Google Scholar]
  12. Pudek M. R., Chan K. W., Rogers P. C., Teasdale J. M. Beta 2-microglobulin levels in cerebrospinal fluid of children with leukemia and lymphoma. Clin Biochem. 1985 Jun;18(3):180–183. doi: 10.1016/s0009-9120(85)80105-3. [DOI] [PubMed] [Google Scholar]
  13. Schold S. C., Wasserstrom W. R., Fleisher M., Schwartz M. K., Posner J. B. Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol. 1980 Dec;8(6):597–604. doi: 10.1002/ana.410080609. [DOI] [PubMed] [Google Scholar]
  14. Shuttleworth E., Allen N. CSF beta-glucuronidase assay in the diagnosis of neoplastic meningitis. Arch Neurol. 1980 Nov;37(11):684–687. doi: 10.1001/archneur.1980.00500600032003. [DOI] [PubMed] [Google Scholar]
  15. Storti S., Pagano L., Marra R., Teofili L., Ricerca B. M., Leone G., Bizzi B. Cerebrospinal fluid beta-2-microglobulin: a reliable index of leukaemic infiltration of central nervous system. Scand J Haematol. 1986 Oct;37(4):301–305. doi: 10.1111/j.1600-0609.1986.tb02316.x. [DOI] [PubMed] [Google Scholar]
  16. Tallman R. D., Kimbrough S. M., O'Brien J. F., Goellner J. R., Yanagihara T. Assay for beta-glucuronidase in cerebrospinal fluid: usefulness for the detection of neoplastic meningitis. Mayo Clin Proc. 1985 May;60(5):293–298. doi: 10.1016/s0025-6196(12)60535-7. [DOI] [PubMed] [Google Scholar]
  17. Twijnstra A., Nooyen W. J., van Zanten A. P., Hart A. A., Ongerboer de Visser B. W. Cerebrospinal fluid carcinoembryonic antigen in patients with metastatic and nonmetastatic neurological diseases. Arch Neurol. 1986 Mar;43(3):269–272. doi: 10.1001/archneur.1986.00520030059015. [DOI] [PubMed] [Google Scholar]
  18. Twijnstra A., van Zanten A. P., Nooyen W. J., Hart A. A., Ongerboer de Visser B. W. Cerebrospinal fluid beta 2-microglobulin: a study in controls and patients with metastatic and non-metastatic neurological diseases. Eur J Cancer Clin Oncol. 1986 Apr;22(4):387–391. doi: 10.1016/0277-5379(86)90103-3. [DOI] [PubMed] [Google Scholar]
  19. Wasserstrom W. R., Glass J. P., Posner J. B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982 Feb 15;49(4):759–772. doi: 10.1002/1097-0142(19820215)49:4<759::aid-cncr2820490427>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  20. van Zanten A. P., Twijnstra A., Hart A. A., Ongerboer de Visser B. W. Cerebrospinal fluid lactate dehydrogenase activities in patients with central nervous system metastases. Clin Chim Acta. 1986 Dec 30;161(3):259–268. doi: 10.1016/0009-8981(86)90009-4. [DOI] [PubMed] [Google Scholar]
  21. van Zanten A. P., Twijnstra A., Ongerboer de Visser B. W., Hart A. A., Nooyen W. J. Tumour markers in the cerebrospinal fluid of patients with central nervous system metastases from extracranial malignancies. Clin Chim Acta. 1988 Jul 15;175(2):157–166. doi: 10.1016/0009-8981(88)90005-8. [DOI] [PubMed] [Google Scholar]
  22. van Zanten A. P., Twijnstra A., Ongerboer de Visser B. W. Routine investigations of the CSF with special reference to meningeal malignancy and infectious meningitis. Acta Neurol Scand. 1988 Mar;77(3):210–214. doi: 10.1111/j.1600-0404.1988.tb05896.x. [DOI] [PubMed] [Google Scholar]
  23. van Zanten A. P., Twijnstra A., van Benthem V., Hart A. A., Ongerboer de Visser B. W. Cerebrospinal fluid beta-glucuronidase activities in patients with central nervous system metastases. Clin Chim Acta. 1985 Apr 15;147(2):127–134. doi: 10.1016/0009-8981(85)90073-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES